Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer

被引：0
|
作者：
Hiroyuki Okuyama
Yoshinori Kagawa
Toshiki Masuishi
Saori Mishima
Hiromichi Shirasu
Koji Ando
Satoshi Yuki
Kei Muro
Takayuki Yoshino
Kentaro Yamazaki
Eiji Oki
Yoshito Komatsu
Akihito Tsuji
机构：
[1] Kagawa University,Department of Clinical Oncology, Faculty of Medicine
[2] Kansai Rosai Hospital,Department of Colorectal Surgery
[3] Aichi Cancer Center Hospital,Department of Clinical Oncology
[4] National Cancer Center Hospital East,Department of Gastrointestinal Oncology
[5] Shizuoka Cancer Center,Division of Gastrointestinal Oncology
[6] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences
[7] Hokkaido University Hospital,Department of Gastroenterology and Hepatology
[8] Hokkaido University Hospital Cancer Center,Department of Cancer Chemotherapy
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Infusion reaction; Ramucirumab; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2025 / 2028
页数：3
相关论文
共 50 条
  • [21] Preventive effect of dexamethasone premedication on the development of infusion-related reaction in breast cancer patients receiving trastuzumab
    Goto, Emi
    Hata, Takeo
    Nishihara, Masami
    Neo, Masashi
    Iwamoto, Mitsuhiko
    Kimura, Kosei
    Goto, Masahiro
    Rikitake, Yoshiyuki
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (07) : 2102 - 2112
  • [22] DaratumumabVarious infusion-related reaction: 7 case reports
    Reactions Weekly, 2022, 1910 (1) : 170 - 170
  • [23] RituximabTingling throat as an infusion-related reaction: case report
    Reactions Weekly, 2019, 1771 (1) : 270 - 270
  • [24] Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    ANTICANCER RESEARCH, 2021, 41 (06) : 3091 - 3097
  • [25] Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
    Sugimoto, Naotoshi
    Matsuda, Chu
    Hata, Taishi
    Satoh, Taroh
    Ikenaga, Masakazu
    Mizushima, Tsunekazu
    Murata, Kohei
    Ohue, Masayuki
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)
    Sugimoto, N.
    Nakata, K.
    Miyo, M.
    Yoshioka, S.
    Kagawa, Y.
    Naito, A.
    Tei, M.
    Tamagawa, H.
    Konishi, K.
    Osawa, H.
    Shingai, T.
    Danno, K.
    Nishida, N.
    Sato, G.
    Shimokawa, T.
    Miyoshi, N.
    Takahashi, H.
    Uemura, M.
    Yamamoto, H.
    Murata, K.
    Doki, Y.
    Eguchi, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S274 - S274
  • [27] Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    ANTICANCER RESEARCH, 2020, 40 (03) : 1605 - 1611
  • [28] Recurrence of infusion-related reaction (IRRs) associated to avimantamab
    Becerra, M. V. Sanchez
    Tagliamento, M.
    Aldea, M.
    Masip, J. Remon
    Gazzah, A.
    Vasseur, D.
    Lavaud, P.
    Frelaut, M.
    Abdayem, P.
    Meyer, M-L.
    Ghigna, M. R.
    Levy, A.
    Botticella, A.
    Aix, S. Ponce
    Barlesi, F.
    Planchard, D.
    Besse, B.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
    Kito, Y.
    Yamazaki, K.
    Shoji, H.
    Yamada, T.
    Tsushima, T.
    Mitani, S.
    Shiraishi, K.
    Yasui, H.
    Hara, H.
    Shimozaki, K.
    Esaki, T.
    Shimokawa, H.
    Kajiura, S.
    Masuishi, T.
    Baba, E.
    Yoshimura, K.
    Kawakami, H.
    Hironaka, S.
    Muro, K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S715 - S715
  • [30] Reduced Incidence of Infusion-Related Reactions in Metastatic Colorectal Cancer During Treatment With Cetuximab Plus Irinotecan With Combined Corticosteroid and Antihistamine Premedication
    Siena, Salvatore
    Glynne-Jones, Robert
    Adenis, Antoine
    Thaler, Josef
    Preusser, Peter
    Aranda Aguilar, Enrique
    Aapro, Matti S.
    Loos, Anja H.
    Esser, Regina
    Wilke, Hansjochen
    CANCER, 2010, 116 (07) : 1827 - 1837
12345